Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

EBS earnings analysis

Filed April 30, 2026 · Our reading of the company's report

The latest report

Emergent BioSolutions reported Q1 2026 earnings with total revenue of $156.1 million, decreasing by 30% compared to Q1 2025. The company achieved an EPS of $0.21, surpassing the estimated loss of $0.25, while…

Read full summary

Emergent BioSolutions reported Q1 2026 earnings with total revenue of $156.1 million, decreasing by 30% compared to Q1 2025. The company achieved an EPS of $0.21, surpassing the estimated loss of $0.25, while experiencing significant declines in its MCM product sales. Management remains cautiously optimistic, projecting Q2 2026 revenues between $170 million and $185 million, driven by improved operations and product sales.

Read the original on SEC.gov

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $59 Operating expenses $34 Left as operating profit $7

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

Reported figures

Earnings per share
$0.21
Segment
Commercial Products
Segment
MCM Products

What stood out

  • EPS Surprising Improvement

    Reported EPS of $0.21 compared to an expected loss of $0.25, translating to a surprise of 1.84%.

  • Improved Cash Position

    Cash and cash equivalents decreased to $160.3 million from $205.4 million, but available borrowing capacity remains strong.

  • Operational Expense Reduction

    Total operating expenses decreased by 15% to $145.6 million from $172.3 million, highlighting cost management efforts.

  • Decline in Interest Expense

    Interest expense decreased by 25% to $11.0 million from $14.7 million due to lower outstanding debt.

  • Segment Performance Review

    MCM Product revenue dropped 35% from $156.6 million in Q1 2025 to $101.8 million in Q1 2026.

  • Share Repurchase Program Ongoing

    $9.1 million used in stock repurchases in Q1 2026, with $46.5 million remaining under the repurchase plan.

What to watch

  • Significant Revenue Decline

    Total revenues decreased by $66.1 million, or 30%, due to lower MCM product sales.

  • High Cost of Debt

    Total debt remained stable at $573.6 million, maintaining high financing costs amid decreased revenues.

  • Reliance on Third-Party Manufacturers

    Dependence on third-party manufacturers for product supply can disrupt operations and affect profitability.

Management's outlook

Q2 2026 guidance reflects expectations of improved operations and product sales.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.